JACC. Case reports · 2025
High-Sensitivity Troponin 1 as a Potential Prognostic Biomarker for HFpEF in Low-Income Rural Settings.
Клинический случайСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Mallasandra Balakrishna Arjun, B Shetty Sreekanth, Krishnamurthy Deepak
Аннотация
BACKGROUND: Heart failure causes high morbidity and mortality globally, especially in low- and middle-income countries, highlighting the need for affordable, accessible, and effective biomarkers.
OBJECTIVES: To evaluate the prognostic utility of high-sensitivity cardiac troponin 1 (hs-cTn1) levels in predicting rehospitalization, major adverse cardiovascular event (MACE), and mortality rates among patients who have heart failure with preserved ejection fraction (HFpEF).
METHODS: In a prospective observational study, 94 patients diagnosed with HFpEF were stratified based on their admission hs-cTn1 level into 4 groups. The patients were evaluated for 12 months to study rehospitalization rates, incidence of MACE, and mortality.
RESULTS: Patients with hs-cTn1 level >30 ng/L exhibited the highest rates of rehospitalization (72.7%), MACE (81.8%), and mortality (36.4%). A stepwise decrease in these events was observed with lower hs-cTn1 levels. Statistical analysis confirmed significant associations between hs-cTn1 concentrations and all measured outcomes.
CONCLUSIONS: Results indicated that hs-cTn1 serves as a potent prognostic biomarker for HFpEF, with higher levels indicating greater risks of rehospitalization, MACE, and mortality.
TAKE-HOME MESSAGE: Elevated high-sensitivity cardiac troponin 1 (hs-cTn1) levels are strongly associated with increased risks of rehospitalization, major adverse cardiovascular events, and mortality in heart failure patients. Given its affordability and accessibility, hs-cTn1 testing can emerge as a practical tool for early risk stratification in resource-limited settings.
OBJECTIVES: To evaluate the prognostic utility of high-sensitivity cardiac troponin 1 (hs-cTn1) levels in predicting rehospitalization, major adverse cardiovascular event (MACE), and mortality rates among patients who have heart failure with preserved ejection fraction (HFpEF).
METHODS: In a prospective observational study, 94 patients diagnosed with HFpEF were stratified based on their admission hs-cTn1 level into 4 groups. The patients were evaluated for 12 months to study rehospitalization rates, incidence of MACE, and mortality.
RESULTS: Patients with hs-cTn1 level >30 ng/L exhibited the highest rates of rehospitalization (72.7%), MACE (81.8%), and mortality (36.4%). A stepwise decrease in these events was observed with lower hs-cTn1 levels. Statistical analysis confirmed significant associations between hs-cTn1 concentrations and all measured outcomes.
CONCLUSIONS: Results indicated that hs-cTn1 serves as a potent prognostic biomarker for HFpEF, with higher levels indicating greater risks of rehospitalization, MACE, and mortality.
TAKE-HOME MESSAGE: Elevated high-sensitivity cardiac troponin 1 (hs-cTn1) levels are strongly associated with increased risks of rehospitalization, major adverse cardiovascular events, and mortality in heart failure patients. Given its affordability and accessibility, hs-cTn1 testing can emerge as a practical tool for early risk stratification in resource-limited settings.